KOSDAQ - Delayed Quote KRW

Korea Arlico Pharm Co.,Ltd. (260660.KQ)

Compare
3,445.00 -35.00 (-1.01%)
At close: November 29 at 3:30 PM GMT+9
Loading Chart for 260660.KQ
DELL
  • Previous Close 3,480.00
  • Open 3,540.00
  • Bid 3,435.00 x --
  • Ask 3,480.00 x --
  • Day's Range 3,430.00 - 3,540.00
  • 52 Week Range 3,290.00 - 6,090.00
  • Volume 35,071
  • Avg. Volume 158,609
  • Market Cap (intraday) 52.247B
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield 130.00 (3.77%)
  • Ex-Dividend Date Dec 27, 2023
  • 1y Target Est --

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients. The company provides products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.

www.arlico.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 260660.KQ

View More

Performance Overview: 260660.KQ

Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

260660.KQ
39.56%
KOSPI Composite Index
7.51%

1-Year Return

260660.KQ
39.03%
KOSPI Composite Index
2.54%

3-Year Return

260660.KQ
47.43%
KOSPI Composite Index
15.58%

5-Year Return

260660.KQ
53.18%
KOSPI Composite Index
17.62%

Compare To: 260660.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 260660.KQ

View More

Valuation Measures

Annual
As of 11/29/2024
  • Market Cap

    51.72B

  • Enterprise Value

    81.46B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.28

  • Price/Book (mrq)

    0.62

  • Enterprise Value/Revenue

    0.45

  • Enterprise Value/EBITDA

    1.16

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.96%

  • Return on Assets (ttm)

    -4.18%

  • Return on Equity (ttm)

    -10.05%

  • Revenue (ttm)

    178.83B

  • Net Income Avi to Common (ttm)

    -8.86B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.68B

  • Total Debt/Equity (mrq)

    57.45%

  • Levered Free Cash Flow (ttm)

    -22.51B

Research Analysis: 260660.KQ

View More

Company Insights: 260660.KQ

Research Reports: 260660.KQ

View More

People Also Watch